HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells
Abstract Background Chronic myeloid leukemia is associated with a more favorable prognosis following treatment with BCR::ABL1 tyrosine kinase inhibitors (TKIs). Nonetheless, about 40% of affected individuals with CML display resistance or intolerance towards BCR::ABL1 TKIs. Heat shock protein 90 (HS...
Saved in:
Main Authors: | Masanobu Tsubaki, Taira Matsuo, Rie Komori, Noriaki Nagai, Tetsushi Yamamoto, Shozo Nishida |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2025-01-01
|
Series: | Future Journal of Pharmaceutical Sciences |
Subjects: | |
Online Access: | https://doi.org/10.1186/s43094-025-00767-w |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia
by: Aytan Shirinova
Published: (2024-03-01) -
T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy
by: Meng-Tung Hsu, et al.
Published: (2025-01-01) -
The known unknowns of the Hsp90 chaperone
by: Laura-Marie Silbermann, et al.
Published: (2024-12-01) -
Hsp90α promotes lipogenesis by stabilizing FASN and promoting FASN transcription via LXRα in hepatocellular carcinoma
by: Zihao Deng, et al.
Published: (2025-01-01) -
Insights into the Allosteric Regulation of Human Hsp90 Revealed by NMR Spectroscopy
by: Tjaša Goričan, et al.
Published: (2024-12-01)